Discover the new OncoKDM™: enhanced precision for your laboratory

Discover the latest version of our OncoKDM™ analysis software. In addition to delivering a comprehensive interpretation report, our platform now provides an even deeper analysis of QC data, empowering your laboratory with the precision necessary for accurate insights.

What’s new?

Sample level insights

  • Amount of Reads: Track and analyze the total reads with enhanced precision.
  • Mean Reads: Gain insights into the average reads by exons for a clearer analysis.
  • Coverage Uniformity: Ensure consistent coverage across your experiments.
  • Exons with Coverage >100x: Easily identify high-coverage exons critical for your research.
  • Mean Coverage: Obtain average coverage data crucial for quality assessments.

Gene level analysis 

  • Mean Coverage: Understand the average coverage depth across all genes.
  • Total Amount of Exons: Access comprehensive data on exon counts.
  • Mean Coverage and Uniformity by Exons: Dive deeper into exon-specific coverage and uniformity for better clarity.

OncoKDM™ not only simplifies your NGS analysis but also provides an effective platform to leverage your QC data, enhancing both the accuracy and efficiency of your laboratory operations.

You may also be interested in these resources

Scientific Application Note

BREAST CANCER Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients with AKT1E17K-Mutant, ER-Positive Metastatic Breast Cancer

Abstract PURPOSE: The activating mutation AKT1E17K occurs in approximately 7% of estrogen receptor–positive (ER+) metastatic breast cancer (MBC). We report, from a multipart, first-in-human, phase I study, tolerability and activity of capivasertib, an oral AKT inhibitor, as monotherapy...

Share This